NCT06116565 is a Phase 2 clinical trial of CM310 in Atopic Dermatitis, sponsored by Keymed Biosciences Co.Ltd.

Who is sponsoring NCT06116565?

NCT06116565 is sponsored by Keymed Biosciences Co.Ltd.

What drugs are being tested in NCT06116565?

Interventions in NCT06116565: CM310.

What condition does NCT06116565 study?

NCT06116565 studies Atopic Dermatitis.

Is NCT06116565 still recruiting?

NCT06116565 is currently status unknown. Last updated 3 November 2023.

Last reviewed 2023-11-03 · How we verify

NCT06116565

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

A Study of CM310 in Subjects With Moderate-to-Severe Atopic Dermatitis

Status unknown Phase 2 Last updated 3 November 2023

What this trial tests

Phase 2 trial testing CM310 in Atopic Dermatitis in 300 participants. Status unknown.

Timeline

30 March 2024

Primary endpoint
30 March 2026

30 March 2026

Quick facts

Lead sponsor	Keymed Biosciences Co.Ltd
Phase	Phase 2
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	300
Start date	30 March 2024
Primary completion	30 March 2026
Estimated completion	30 March 2026

Drugs / interventions tested

CM310 — full drug profile →

Conditions studied

Atopic Dermatitis — all drugs for Atopic Dermatitis →

Sponsor

Keymed Biosciences Co.Ltd — full company profile →

Who can join

Adults 18 to 75, any sex, with Atopic Dermatitis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a multi-center, open-label phase 2 study to evaluate the long-term safety and efficacy of CM310 in subjects with moderate-to-severe atopic dermatitis.

Publications & conference data

4 peer-reviewed publications reference this trial (live from Europe PMC):

Emerging Biologic Therapies for the Treatment of Atopic Dermatitis.
Alvarenga JM, Bieber T, Torres T. · · 2024 · cited 20× · PMID 39365406 · DOI 10.1007/s40265-024-02095-4
Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives.
Alska E, Łaszczych D, Napiórkowska-Baran K, Szymczak B, et al · · 2025 · cited 13× · PMID 40004611 · DOI 10.3390/jcm14041079
Emerging Systemic Treatment Options in Atopic Dermatitis.
Salman A, Giménez-Arnau AM. · · 2024 · cited 3× · PMID 38966900 · DOI 10.4274/balkanmedj.galenos.2024.2024-5-78
Efficacy and Safety of Extending Dosing Interval of Stapokibart in Patients with Atopic Dermatitis.
Zhao Y, Zhou C, Man X, Liu B, et al · · 2025 · PMID 40711953 · DOI 10.1177/17103568251361896

Verify or expand the search:

Other trials of CM310

Trials testing the same drug.

NCT06547333 — A Study of CM310 in Subjects With Moderate to Severe Chronic Obstructive Pulmonary Disease · Phase 2, PHASE3 · not yet recruiting
NCT06495229 — Study of CM310 in Adolescent Subjects With Atopic Dermatis · Phase 3 · active not recruiting
NCT06171048 — Study Evaluating the Pharmacokinetics of CM310 in Healthy Subjects · Phase 1 · unknown
NCT06171074 — Study of CM310 in Subjects With Seasonal Allergic Rhinitis · Phase 2 · unknown
NCT06277765 — Study of CM310 Injection in Adolescent Subjects With Atopic Dermatis · Phase 3 · completed

Other recruiting trials for Atopic Dermatitis

Currently open trials in the same condition.

NCT07262983 — Evaluating the Safety and Tolerability of Baricitinib in Patients With Job Syndrome With Lupus-Like Disease and/or Atopi · Phase 1 · recruiting
NCT07445919 — A Clinical Study to Evaluate SM17 for Atopic Dermatitis · Phase 2 · recruiting
NCT07488065 — A Study of SKB575 (HBM7575) Injection in Healthy Participants and Atopic Dermatitis Participants · Phase 1 · recruiting
NCT07467564 — The Impact of Dupilumab Treatment on Anxiety and Depression Symptoms in Patients With Moderate-to-Severe Atopic Dermatit · recruiting
NCT07358156 — A Study to Compare the Pharmacokinetics, Pharmacodynamic, Immunogenicity, and Safety of CKD-706 With US-Dupixent®, and E · Phase 1 · recruiting

Other Keymed Biosciences Co.Ltd trials

Trials by the same sponsor.

NCT07519577 — A Study of CM512 in Patients With Chronic Rhinosinusitis With Nasal Polyposis （NEZHA-2） · Phase 2 · not yet recruiting
NCT07166211 — Study of CM512 Injection in Subjects With Chronic Spontaneous Urticaria(CSU) · Phase 2 · recruiting
NCT07175493 — A Study of CM336 in Patients With Relapsed or Refractory Autoimmune Cytopenia · Phase 1, PHASE2 · recruiting
NCT07011524 — Study of CM512 Injection in Subjects With Moderate-to-severe Asthma · Phase 2 · recruiting
NCT07039578 — Study Evaluating the Efficacy and Safety of CM336 Injection in the Treatment of Light-Chain Amyloidosis · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT06116565 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Keymed Biosciences Co.Ltd
Last refreshed: 3 November 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06116565.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing